Serum biomarkers for diagnosis and monitoring viral hepatitis and hepatocellular carcinoma

References

• Biomarkers and surrogate endpoints: preferred definitions and conceptual framework. Clin Pharmacol Ther. 2001 Mar;69(3):89–95.
   PubMed Web of Science ®Google Scholar
• WHO. Position paper on hepatitis A vaccines. Wkly Epidemiol Rec. 2012;87:261–276.
   PubMedGoogle Scholar
• Marissa Gripenberg, Aloysia D’Cor, N., L’Azou, M., et al. Changing sero-epidemiology of hepatitis A in Asia Pacific countries: a systematic review. Int Journal Infect Diseases. 2018;68, 13-17. ISSN 1201-9712
   Web of Science ®Google Scholar
• Feinstone SM, Kapikian AZ, Purcell RH. Hepatitis A: detection by immune electron microscopy of a virus like antigen associated with acute illness. Science. 1973;182:1026–1028.
   PubMed Web of Science ®Google Scholar
• L.Krugmen, S. Infectious hepatitis. Evidence for two distinctive clinical, epidemiological, and immunological types of infection. JAMA. 1967;200:365–373.
   PubMedGoogle Scholar
• Cao J, Wang Y, Song H, et al. Hepatitis A outbreaks in China during 2006: application of molecular epidemiology. Hepatol Int. 2009;3(2):356–363.
   PubMed Web of Science ®Google Scholar
• Leino T, Leinikki P, Hyypia T, et al. Hepatitis A outbreak amongst intravenous amphetamine abusers in Finland. Scand J Infect Dis. 1997;29:213–216.
   PubMed Web of Science ®Google Scholar
• Henning KJ, Bell E, Braun J, et al. A communitywide outbreak of hepatitis A: risk factors for infection among homosexual and bisexual men. Am J Med. 1995;99:132–136.
   PubMed Web of Science ®Google Scholar
• Steffen R, Kane MA, Shapir CN, et al. Epidemiology and prevention of hepatitis A in travelers. JAMA. 1994;272:885–889.
   PubMed Web of Science ®Google Scholar
• Innis BL, Snitbhan R, Kunasol P, et al. Protection against hepatitis A by an inactivated vaccine. JAMA. 1994;271:1328–1334.
   PubMed Web of Science ®Google Scholar
• Nalin DR, Kuter BJ, Brown L, et al. Worldwide experience with the CR326F-derived inactivated hepatitis A virus vaccine in pediatric and adult populations: an overview. J Hepatol. 1993;18(Suppl 2):s51–s55.
   PubMedGoogle Scholar
• Lemon SM, Ott JJ, Van Damme P, et al. Type A viral hepatitis: a summary and update on the molecular virology, epidemiology, pathogenesis and prevention. J Hepatol. 2017 Sep 5. DOI:10.1016/j.jhep.2017.08.034.
   PubMed Web of Science ®Google Scholar
• Nainan OV, Xia G, Vaughan G, et al. Diagnosis of hepatitis A virus infection: a molecular approach. Clin Microbiol Rev. 2006 Jan;19(1):63–79.
   PubMed Web of Science ®Google Scholar
• Kao HW, Ashcavai M, Redeker AG. The persistence of hepatitis A IgM antibody after acute clinical hepatitis A. Hepatology. 1984;4:933–936.
   PubMed Web of Science ®Google Scholar
• Angarano G, Trotta F, Monno L, et al. Serum IgA anti-hepatitis A virus as detected by enzyme-linked immunosorbent assay: diagnostic significance in patients with acute and protracted hepatitis A. Diagn Microbiol Infect Dis. 1985;3:521–523.
   PubMed Web of Science ®Google Scholar
• Hurni WM, Laufer D, Miller WJ, et al. Anti-hepatitis A in the general population and in hepatitis A vaccinees using saliva and serum as diagnostic media. Ann NY Acad Sci. 1993;694:289–292.
   PubMed Web of Science ®Google Scholar
• Jacobson SK, Buttery R, Parry JV, et al. Investigation of a hepatitis A outbreak in a primary school by sequential saliva sampling. Clin Diagn Virol. 1995;3:173–180.
   PubMedGoogle Scholar
• Iqbal K. Epidemiology of acute hepatitis B in the United States from population-based surveillance, 2006–2011. Clin Infect Dis. 2015 Aug 15;61(4):584–592.
   PubMed Web of Science ®Google Scholar
• Razavi-Shearer D, Gamkrelidze I, Nguyen MH, , et al. Global prevalence, treatment, and prevention of hepatitis B infection in 2016: a modelling study. Lancet Gastroenterol Hepatol. 2018 Jun; 3(6):383–403.
   PubMed Web of Science ®Google Scholar
• Aspinall EJ, Hawkins G. A. Fraser et al. Hepatitis B prevention, diagnosis, treatment and care: a review. Occup Med (Chic Ill). 2011 Dec 1;61(8):531–540.
   Web of Science ®Google Scholar
• Blumberg BS, Alter HJ. Visnic. A ‘new’ antigen in leukemia sera. JAMA. 1965;196:541–546.
   Google Scholar
• Lin CL, Kao JH. Hepatitis B viral factors and treatment responses in chronic hepatitis B. J Formos Med Assoc. 2013;112:302–311.
   PubMed Web of Science ®Google Scholar
• Thomas HC. Best practice in the treatment of chronic hepatitis B: a summary of the European Viral Hepatitis Educational Initiative (EVHEI). J Hepatol. 2007;47:588–597.
   PubMed Web of Science ®Google Scholar
• EASL 2017. clinical practice guidelines on management of hepatitis B infection. J Hepatol. 2017;67:370–398.
   PubMed Web of Science ®Google Scholar
• Chen C-J, Yang H-I, Iloeje UH, The REVEAL-HBV Study Group. Hepatitis B virus DNA levels and outcomes in chronic hepatitis B. Hepatology. 2009;49:S72–S84. .
   PubMed Web of Science ®Google Scholar
• Nguyen T, Thompson AJV, Bowden S, et al. Hepatitis B surface antigen levels during the natural history of chronic hepatitis B: a perspective on Asia. J Hepatology 2010. 52:508–513.
   PubMed Web of Science ®Google Scholar
• Martinot-Peignoux M, Lapalus M, Asselah T, et al. HBsAg quantification: useful for monitoring natural history and treatment outcome. Liver Int. 2014;34(Suppl 1):97–107.
   PubMedGoogle Scholar
• Thompson AJ, Nguyen T, Iser D, et al. Serum hepatitis B surface antigen and hepatitis B e antigen titers: disease phase influences correlation with viral load and intrahepatic hepatitis B virus markers. Hepatology. 2010;51:1933–1944.
   PubMed Web of Science ®Google Scholar
• Chan HL, Wong VW, Tse AM, et al. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol. 2007;5:1462–1468.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Liu CJ, Su TH, et al. Serum hepatitis B surface antigen levels predict surface antigen loss in hepatitis B e antigen seroconverters. Gastroenterology. 2011;141:517–525.
   PubMed Web of Science ®Google Scholar
• Cornberg M, Wong VW-S, Locarnini S, et al. The role of quantitative hepatitis B surface antigen revisited. J Hepatol. 2017 Feb;66(2):398–411.
   PubMed Web of Science ®Google Scholar
• Magnius LO, Espmark JA. New specificities in Australia antigen positive sera distinct from the Le Bouvier determinants. J Immunol. 1972;109:1017.
   PubMed Web of Science ®Google Scholar
• Yang HI, Lu SN, You SL, et al. Hepatitis B e antigen and risk of hepatocellular carcinoma. N Engl J Med. 2002;347:168–174.
   PubMed Web of Science ®Google Scholar
• Chen C, Yang H, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA. 2006;295(1):65–73.
   PubMed Web of Science ®Google Scholar
• Lin S-M, Sheen I-S, Chien R-N, et al. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology. 1999;29:971–975.
   PubMed Web of Science ®Google Scholar
• Perrillo R, Mimms L, Schechtman K, et al. Monitoring of antiviral therapy with quantitative evaluation of HBeAg: a comparison with HBV DNA testing. Hepatology. 1993 Dec;18(6):1306–1312.
   PubMed Web of Science ®Google Scholar
• Lee JM, Ahn SH, Kim HS, et al. Quantitative hepatitis B surface antigen and hepatitis B e antigen titers in prediction of treatment response to entecavir. Hepatology. 2011;53:1486–1493.
   PubMed Web of Science ®Google Scholar
• Raimondo G, Allain JP, Brunetto MR, et al. Statements from the Taormina expert meeting on occult hepatitis B virus infection. J Hepatol. 2008 Oct;49(4):652–657.
   PubMed Web of Science ®Google Scholar
• Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev. 2000;64(1):51–68.
   PubMed Web of Science ®Google Scholar
• Li A, Yuan Q, Huang Z, et al. Novel double antigen sandwich immunoassay for human hepatitis B core antibody. Clin Vaccine Immunol. 2010;17:464–469.
   PubMed Web of Science ®Google Scholar
• Yuan Q, Song LW, Liu CJ, et al. Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients. Gut. 2013;62:182–184.
   PubMed Web of Science ®Google Scholar
• Fan R, Sun J, Yuan Q, et al. Baseline quantitative hepatitis B core antibody titre alone strongly predicts HBeAg seroconversion across chronic hepatitis B patients treated with peginterferon or nucleos(t)ide analogues. Gut. 2016;65:313–320.
   PubMed Web of Science ®Google Scholar
• Kimura T, Rokuhara A, Sakamoto Y, et al. Sensitive enzyme immunoassay for hepatitis B virus corerelated antigens and their correlation to virus load. J Clin Microbiol. 2002;40:439–445.
   PubMed Web of Science ®Google Scholar
• Song G, Yang R, Rao H, et al. Serum HBV corerelated antigen is a good predictor for spontaneous HBeAg seroconversion in chronic hepatitis B patients. J Med Virol. 2016 Aug; 89(3), 463–469.
   Web of Science ®Google Scholar
• Tanaka E, Matsumoto A, Suzuki F, et al. Measurement of hepatitis B virus core-related antigen is valuable for identifying patients who are at low risk of lamivudine resistance. Liver Int. 2006;26:90–96.
   PubMed Web of Science ®Google Scholar
• Wong DK, Tanaka Y, Lai CL, et al. Hepatitis B virus core-related antigens as markers for monitoring chronic hepatitis B infection. J Clin Microbiol. 2007;45:3942–3947.
   PubMed Web of Science ®Google Scholar
• Suzuki F, Miyakoshi H, Kobayashi M, et al. Correlation between serum hepatitis B virus core-related antigen and intrahepatic covalently closed circular DNA in chronic hepatitis B patients. J Med Virol. 2009;81:27–33.
   PubMed Web of Science ®Google Scholar
• L-Y M. Alimen Pharmacol Ther. 2018;47:43–54.
   PubMed Web of Science ®Google Scholar
• Kumada T, Toyoda H, Tada T, et al. Effect of nucleos(t)ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients: a propensity score analysis. J Hepatol. 2013;58:427–433.
   PubMed Web of Science ®Google Scholar
• Honda M, Shirasaki T, Terashima T, et al. HBcrAg during nucleos(t)ide analog therapy are related to intra-hepatic HBV replication and development of hepatocellular carcinoma. J Infect Dis. 2016;213:1096–1106.
   PubMed Web of Science ®Google Scholar
• Tada T, Kumada T, Toyoda H, et al. HBcrAg predicts hepatocellular carcinoma development: an analysis using time-dependent receiver operating characteristics. J Hepatol. 2016;65:48–56.
   PubMed Web of Science ®Google Scholar
• Hosaka T, Suzuki F, Kobayashi M, et al. “HBcrAg Is a Predictor of Post-Treatment Recurrence of Hepatocellular Carcinoma During Antiviral Therapy.” Liver International 30.10 (2010):1461–1470.
   Google Scholar
• Van Bömmel, F, Bartens A, Mysickova A, et al. Serum hepatitis B virus RNA levels as an early predictor of hepatitis B envelope antigen seroconversion during treatment with polymerase inhibitors. Hepatology. 2015;61:66–76, Wang J et al. J hepatol 2016;65:700–710
   PubMed Web of Science ®Google Scholar
• Rizzetto M, Canese MG, Arico S, et al. Immunofluorescence detection of new antigen-antibody system (delta/anti-delta) associated to hepatitis B virus in liver and in serum of HBsAg carriers. Gut. 1977;18:997–1003.
   PubMed Web of Science ®Google Scholar
• Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: update and challenges ahead. Nat Rev Gastroenterol Hepatol. 2010;7:31–40.
   PubMed Web of Science ®Google Scholar
• Hughes SA, Wedemeyer H, Harrison PM. Hepatitis delta virus. The Lancet. 2011; 378(9785):73–85
   PubMed Web of Science ®Google Scholar
• Zachou K, C. Yurdaydin U, Drebber GN, et al. Quantitative HBsAg and HDV-RNA levels in chronic delta hepatitis. Liver Int. 2010;30(3):430–437.
   PubMed Web of Science ®Google Scholar
• Choo QL, Kuo G, Weiner A, et al. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989;244:359–362.
   PubMed Web of Science ®Google Scholar
• Lingala S, Ghany MG. Natural history of hepatitis C. Gastroenterol Clin North Am. 2015;44:717–734.
   PubMed Web of Science ®Google Scholar
• Seeff LB. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: a national heart, lung, and blood institute collaborative study. Hepatology. 2001;33:455–463.
   PubMed Web of Science ®Google Scholar
• Biasiolo A. New biomarkers for clinical management of hepatitis C virus infected patients. World J Clin Infect Dis. 2015;5:59.
   Google Scholar
• Fattovich G, Pantalena M, Zagni I, et al. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol. 2002;97(11):2886–2895.
   PubMed Web of Science ®Google Scholar
• Benvegnu L, Gios M, Boccato S, et al. Natural history of compensated viral cirrhosis: a prospective study on the incidence and hierarchy of major complications. Gut. 2004;53(5):744–749.
   PubMed Web of Science ®Google Scholar
• Serfaty L, Aumaitre H, Chazouilleres O, et al. Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology. 1998;27(5):1435–1440.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463–472.
   PubMed Web of Science ®Google Scholar
• Perz JF, Armstrong GL, Farrington LA, et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. J Hepatol. 2006;45(4):529–538.
   PubMed Web of Science ®Google Scholar
• Valva P, Ríos DA, De Matteo E, et al. Chronic hepatitis C virus infection: serum biomarkers in predicting liver damage. World J Gastroenterol. 2016;22(4):1367–1381.
   PubMed Web of Science ®Google Scholar
• Ghany MG, Strader DB, Thomas DL, et al. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49(4):1335–1374.
   PubMed Web of Science ®Google Scholar
• Blach, Sarah, Zeuzem S, Manns M, et al. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study. The Lancet Hastroenterology & Hepatology. 2017; 2(3):161–176.
   PubMed Web of Science ®Google Scholar
• Mengshol JA, Golden-Mason L, Rosen HR. Mechanisms of disease: HCV-induced liver injury. Nat Clin Pract Gastroenterol Hepatol. 2007;4(11):622–634.
   PubMedGoogle Scholar
• Chevaliez S, Pawlotsky J-M. How to use virological tools for optimal management of chronic hepatitis C. Liver Int. 2009;29(Suppl 1(6)):9–14.
   PubMedGoogle Scholar
• Butcher A, Aslam S, Hemyari P, et al. HCV RNA detection in HCV antibody-positive patients with the COBAS®AmpliPrep/COBAS®TaqMan®HCV test, v2.0 in comparison with FDA-approved nucleic acid tests. J Clin Virol. 2014;60(4):336–340.
   PubMed Web of Science ®Google Scholar
• Tillmann HL. Hepatitis C virus core antigen testing: role in diagnosis, disease monitoring and treatment. World J Gastroenterol. 2014;20(22):6701–6706.
   PubMed Web of Science ®Google Scholar
• Liu B, Xiang Y, Zhang H-S. Circulating microRNA-196a as a candidate diagnostic biomarker for chronic hepatitis C. Mol Med Rep. 2015;12(1):105–110.
   PubMed Web of Science ®Google Scholar
• Sarrazin C, Wedemeyer H, Cloherty G, et al. Importance of very early HCV RNA kinetics for prediction of treatment outcome of highly effective all oral direct acting antiviral combination therapy. J Virol Methods. 2015;214:29–32.
   PubMed Web of Science ®Google Scholar
• Fytili P, Tiemann C, Wang C, et al. Frequency of very low HCV viremia detected by a highly sensitive HCV-RNA assay. J Clin Virol. 2007;39(4):308–311.
   PubMed Web of Science ®Google Scholar
• Fourati S, Feld JJ, Chevaliez S, et al. Approaches for simplifies HCV diagnostic algorithms. J Int AIDS Soc. 2018;21(S2);e25058.
   Google Scholar
• Waldenström J, Konar J, Ekermo B, et al. Neonatal transfusion-transmitted hepatitis C virus infection following a pre-seroconversion window-phase donation in Sweden. Scand J Infect Dis. 2013;45:796–799.
   PubMed Web of Science ®Google Scholar
• Khan H, Hill A, Main J, et al. Can Hepatitis C Virus Antigen Testing Replace Ribonucleic Acid Polymearse Chain Reaction Analysis for Detecting Hepatitis C Virus? A Systematic Review. Open Forum Infectious Diseases. 2017;4(2):ofw252.
   Google Scholar
• Aggarwal R. The global prevalence of hepatitis E virus infection and susceptibility: a systematic review. Geneve, Switzerland: WHO; 2010.
   Google Scholar
• Hoofnagle JH, Nelson KE, Purcell RH. Hepatitis E. NEJM. 2012;1237–1244.
   PubMedGoogle Scholar
• Bendall R, Ellis V, Ijaz S, et al. A comparison of two commercially available anti-HEV IgG kits and a re-evaluation of anti-HEV IgG seroprevalence data in developed countries. J Med Virol. 2010;82(5):799–805.
   PubMed Web of Science ®Google Scholar
• Taneja S, Sen S, Gupta VK, et al. Plasma and urine biomarkers in acute viral hepatitis E. In: Proteome Sci.
   Google Scholar
• Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol. 2003;18(3):253–257.
   PubMed Web of Science ®Google Scholar
• Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol. 2005;11(4):476–481.
   PubMed Web of Science ®Google Scholar
• Sanvisens A, Serra I, Tural C, et al. Hyaluronic acid, transforming growth factor-beta1 and hepatic fibrosis in patients with chronic hepatitis C virus and human immunodeficiency virus co-infection. J Viral Hepat. 2009;16(7):513–518.
   PubMed Web of Science ®Google Scholar
• Valva P, Casciato P, Diaz Carrasco JM, et al. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis C virus chronic infection. PLoS One. 2011;6(8):e23218.
   PubMed Web of Science ®Google Scholar
• Plevris JN, Haydon GH, Simpson KJ, et al. Serum hyaluronan – A non-invasive test for diagnosing liver cirrhosis. Eur J Gastroenterol Hepatol. 2000;12(10):1121–1127.
   PubMed Web of Science ®Google Scholar
• Wong VS, Hughes V, Trull A, et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepat. 1998;5(3):187–192.
   PubMed Web of Science ®Google Scholar
• Gressner OA, Weiskirchen R, Gressner AM. Biomarkers of hepatic fibrosis, fibrogenesis and genetic pre-disposition pending between fiction and reality: hepatic fibrosis. J Cell Mol Med. 2007;11(5):1031–1051.
   PubMed Web of Science ®Google Scholar
• Baranova A, Lal P, Birerdinc AYZ. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol. 2011;11:91.
   PubMed Web of Science ®Google Scholar
• Imbert-Bismut F, Ratziu V, Pieroni L, et al. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001;357(9262):1069–1075.
   PubMed Web of Science ®Google Scholar
• Myers RP, Tainturier MH, Ratziu V, et al. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003;39(2):222–230.
   PubMed Web of Science ®Google Scholar
• Giannini E, Risso D, Botta F, et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med. 2003;163(2):218–224.
   PubMedGoogle Scholar
• Sebastiani G, Gkouvatsos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol. 2014;20(32):11033–11053.
   PubMed Web of Science ®Google Scholar
• Sebastiani G, Alberti A. Non-invasive fibrosis biomarkers reduce but not substitute the need for liver biopsy. World J Gastroenterol. 2006;12(23):3682–3694.
   PubMed Web of Science ®Google Scholar
• Stuver S, Trichopoulos D. Cancer of the liver and biliary tract. In: editors, Adami HO, Hunter D, Trichopoulos D. Textbook of Cancer Epidemiology. 2nd ed. New York: Oxford University Press; 2008.
   Google Scholar
• The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level results from the global burden of disease study 2015. JAMA Oncol. 2017;3(12):1683–1691.
   PubMed Web of Science ®Google Scholar
• Lang K, Danchenko N, Gondek K, et al. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89–99.
   PubMed Web of Science ®Google Scholar
• Bergstrand CG, Czar B. Demonstration of a new protein fraction in serum from the human fetus. Scand J Clin Lab Invest. 1956;8:174.
   PubMed Web of Science ®Google Scholar
• Tonami N, Aburano T, Hisada K. Comparison of alpha1 fetoprotein radioimmunoassay method and liver scanning for detecting primary hepatic cell carcinoma. Cancer. 1975;36:466–470.
   PubMed Web of Science ®Google Scholar
• Seregni E, Botti C, Bombardieri E, et al. Biochemical characteristics and clinical applications of alpha-fetoprotein isoforms. Anticancer Res. 1995;15:1491–1499.
   PubMed Web of Science ®Google Scholar
• European Association For The Study Of The Liver; European Organisation For Research And Treatment Of Cancer. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2012;56:908–943.
   PubMed Web of Science ®Google Scholar
• Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int. 2010;4:439–474.
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–1022.
   PubMed Web of Science ®Google Scholar
• Waidely E, Al-Yuobi AR, Bashammakh AS, et al. Serum protein biomarkers relevant to hepatocellular carcinoma and their detection. Analyst. 2016;141:36–44.
   PubMed Web of Science ®Google Scholar
• Wang CS, Lin CL, Lee HC, et al. Usefulness of serum des-gamma-carboxy pro-thrombin in detection of hepatocellular carcinoma. World J Gastroenterol. 2005;11:6115–6119.
   PubMed Web of Science ®Google Scholar
• Li D, Mallory T, Satomura S, et al. AFP-L3: a new generation of tumor marker for hepatocellular carcinoma. Clin Chim Acta. 2001;313:15–19.
   PubMed Web of Science ®Google Scholar
• Leerapun A, Suravarapu SV, Bida JP, et al. The utility of lns culinaris agglutinin-reactive alpha-fetoprotein in the diagnosis of hepatocellular carcinoma: evaluation in a United States referral population. Clin Gastroenterol Hepatol. 2007;5:394–402, quiz 267
   PubMed Web of Science ®Google Scholar
• Cheng J, Wang W, Zhang Y, et al. Prognostic role of pre-treatment serum AFP-L3% in hepatocellular carcinoma: systematic review and meta-analysis. PLoS One. 2014;9:e87011.
   PubMedGoogle Scholar
• Zhu WW, Guo JJ, Guo L, et al. Evaluation of midkine as a diagnostic serum biomarker in hepatocellular carcinoma. Clin Cancer Res. 2013;19:3944–3954.
   PubMed Web of Science ®Google Scholar
• Omata M, Cheng A-L, Kokudo N, et al. Asian-Pacific clinical practice guidelines on management of hepatocellular carcinoma: a 2017 update. Hepatol Int. 11. Springer Nature; 2017 Jun 15;11(4):317–70.
   PubMed Web of Science ®Google Scholar
• Sodek J, Ganss B, McKee MD. Osteopontin. Crit Rev Oral Biol Med. 2000;11:279–303.
   PubMedGoogle Scholar
• Dai M, Chen X, Liu X, et al. Diagnostic value of the combination of Golgi protein 73 and alpha-fetoprotein in hepatocellular carcinoma: A meta-analysis. PLoS One. 2015;10:e0140067.
   PubMed Web of Science ®Google Scholar
• Witjes CD, Van Aalten SM, Steyerberg EW, et al. Recently introduced biomarkers for screening of hepatocellular carcinoma: a systematic review and meta-analysis. Hepatol Int. 2013;7:59–64.
   PubMed Web of Science ®Google Scholar
• Capurro M, Wanless IR, Sherman M, et al. Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma. Gastroenterology. 2003;125:89–97.
   PubMed Web of Science ®Google Scholar
• Hyun KA, Kim J, Gwak H, et al. Isolation and enrichment of circulating biomarkers for cancer screening, detection, and diagnostics. Analyst. 2016;141:382–392.
   PubMed Web of Science ®Google Scholar
• Van Hees, Michielsen P, Vanwolleghem T. Circulating predictive and diagnostic biomarkers for HBV-associated HCC. WJG. 2016;22:8271–8282.
   PubMed Web of Science ®Google Scholar